MT-RNR1 testing (Pharmacogenetics)
EQA Scheme for Detection of MT-RNR1 Variants Associated with Aminoglycoside-Induced Hearing Loss.
Overview
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
At a glance
Product Code:
05-PHARM-MTR1-27
Target/Genes:
Technology:
NGS, PCR based, Sanger sequencing, Whole exome sequencing, Whole genome sequencing
Sample Type:
DNA (in TE Buffer)
Submit Results In:
English, French, German, Italian, Spanish
Accredited:
No
Key Dates
01/03/2027
Jun-27
June - August 2027 (for exact dates see scheme instructions).
December 2027 - January 2028
Sample Details
Two or three mock clinical cases with matching samples. Approximately 1-2µg DNA per sample is provided. Complete
information will be available in the scheme instructions.
EQA Results
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participation Information
Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
Send your enquiry by submitting the form
Closes in 112 days
From £380.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
- Submit results in 5 languages
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.